News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
Health & Biotech
When your guts have gone nuts, who do you call? These ASX stocks are fighting gastrointestinal disease
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
Check out these 5 exciting ASX microcaps solving the world’s biggest health issues
Health & Biotech
Health: China loves Aussie food, maybe next it’ll love MVP’s Green Whistle too
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
Check-up: Takeover bid puts workplace health solutions provider Konekt on top
News
Lunchtime ASX small cap wrap: Who’s smashing through the window?
Health & Biotech
Health: “New Gastro Weapon” sends Immuron shares flying 124pc
News
10 at 10: These ASX stocks are bouncing higher this morning
Health & Biotech
Health: Orthocell has done it again as patients regain shoulder function following CelGro surgery
News
Rise and Shine: What you need to know before the ASX opens
News
Lunchtime ASX small cap wrap: Who’s calling all the right shots today?
Health & Biotech
Health: Great day for Paradigm as knee data drops and $78m cap raise opens
Health & Biotech
Immuron’s diarrhoea solution pushes revenue to record level
Health & Biotech
No crap: Immuron is one step closer to an anti-gastro pill
Health & Biotech